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ABSTRACT 
Methotrexate (MTX) is a key component in treatment of 
childhood ALL. Impaired polyglutamation is a known 
mechanism of MTX-resistance. To date, a spectrum of 
splicing alterations was identified for folypoly-γ-glutamate 
synthetase (FPGS), the enzyme which catalyzes 
polyglutamation. The serine/arginine-rich splicing factor 1 
(SRSF1) is involved in both constitutive and alternative 
splicing. We found an association between the expression 
of SRSF1 isoforms, ASF1 and ASF3, and alternative splice 
variants of FPGS. Moreover, in a subgroup of patients with 
deficient polyglutamation, the ratio of ASF3 to ASF1 was 
associated with survival. Therefore splice regulators are 
potential prognostic markers for both patient stratification 
and personalized medicine  in childhood ALL. 
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INTRODUCTION 
Acute lymphoblastic leukemia (ALL) is the most common 
type of blood cancer in children. The 5-year overall 
survival rates of childhood ALL currently reach as high as 
90%.1  However, still in a large proportion of these 
children, treatment failure results in relapse, which is 
largely caused by drug resistance. Since methotrexate 
(MTX) is a key component used during treatment of 
pediatric ALL, it is important to unravel the mechanisms 
behind MTX resistance and treatment failure in children 
with ALL.2  
 
Polyglutamation is an important metabolic conversion, 
which influences the mode of action of MTX. Folypoly-γ-
glutamate synthetase (FPGS) catalyzes polyglutamylation 
of folates and antifolates, such as MTX. Interpersonal 
differences and sometimes loss of FPGS activity has been 
reported in patient samples of children with ALL.3 Because 
of the frequent lack of any substantial decrease in FPGS 
mRNA levels in combination with decreased FPGS 
activity, the contribution of posttranscriptional 
mechanisms to decreased FPGS activity is of interest. To 
date, a spectrum of FPGS splicing products was 
characterized in both ALL patient samples of children and 
cell lines.4  Moreover, high levels of partial intron 8 
retention (8 PR), one of the FPGS splicing alterations 
identified in ALL, is significantly associated with overall 
survival and event free survival in patients with impaired 
accumulation of long chain MTX polyglutamates.5 
Therefore it is essential to characterize the mechanisms 
behind this phenomenon.  
 
The process of alternative splicing is tightly regulated by a 
range of factors, including splicing factors. Pilot analysis 
points to differences in expression of serine/arginine-rich 
splicing factor 1 (SRSF1) isoforms between MTX resistant 
and sensitive cell lines. In general, SRSF1 is a well-
documented splicing factor essential for both constitutive 
and alternative splicing. SRSF1 promotes spliceosome 
assembly and facilitates splice site selection.6 ASF1, ASF2 
and ASF3 (alternative splice factor 1,2 and 3) are isoforms 
of SRSF1 which themselves are generated by alternative 
splicing. ASF2 and ASF3 are predicted to lack the 
serine/arginine rich (RS) domain and 12 residues 
immediately upstream of it, due to an early stop codon 
inserted by intron retention, in comparison to ASF1. The 
RS domain is thought to be required for protein-protein 
interaction of SR proteins with each other and with other 
components of the splicing machinery.78  
 
In the present study we investigate the role of SRSF1 in 
regulation of FPGS splicing and MTX resistance. ASF2 
isoform is rather uncommon, most likely degraded by the 
nonsense-mediated decay pathway (NMD), and therefore 
unlikely to influence the splicing of FPGS.   Therefore, this 
study primarily focuses on the differences in expression 
between isoforms ASF3 and ASF1 in relation to 
alternatively spliced fragments of FPGS and MTX 
sensitivity.  
 
MATERIAL AND METHODS 
 
Antibodies  and Reagents 
Mouse monoclonal SF2/ASF antibody was obtained from 
Santa Cruz (Dallas, TX, USA). Infrared secondary 
antibodies (anti-mouse and anti-rabbit) were obtained from 
Li-Cor (Lincoln, NE, USA). 
 
Cell Culture  
The human T-cell acute lymphocytic leukemia cell lines 
CCFR-CEM (ATCC, Manassas, VA, USA) and its two 
MTX-resistant sublines, CCRF CEM/R30dm and CCRF-
CEM/RFC-, were maintained in RPMI-1640 medium 
containing 10% FCS and 1% penicillin/streptomycin. The 
MTX-resistant cell lines used in this study include: CEM-
CCRF/R30dm which shows diminished FPGS activity 
(only 1-3 percent) while mRNA levels are not affected, 
was kindly provided by John McGuire. CCRF-CEM/RFC- 
displays decreased RFC activity caused by 2 inactivating 
mutations and thereby affects transport of MTX into the 
cell.  
 
 
 
Permission to make digital or hard copies of all or part of this work for 
personal or classroom use is granted under the conditions of the Creative 
Commons Attribution-Share Alike (CC BY-SA) license and that copies 
bear this notice and the full citation on the first page 
 
SRC 2015, November 11, 2015, The Netherlands. 
 
C
E
M
/R
F
C
- 
  
  
  
  
  
 C
E
M
/R
3
0
d
m
  
  
  
  
 C
E
M
/W
T
 
A B 
0    100  250  500 1000  0   100  250 500 1000 
 
Leukemic Patient Specimens 
Bone marrow and/or peripheral blood samples were 
collected from 71 children with ALL at diagnosis after 
obtaining a written informed consent. Mononuclear cells 
were purified using Ficoll density separation. 
Cyropreserved cells were thawed and subsequently used 
for RNA isolation as described below. 
 
Drug exposure 
One million exponentially growing cells were exposed to 
a dose range (0nM, 100nM, 250nM, 500nM and 1000nM) 
of MTX for 24 hours. After exposure, cells were harvested 
by centrifugation and used for RNA extraction. For 
western blot analysis, twenty million cells from the 
logarithmic phase of growth were exposed to 1µM of MTX 
for 24 hours. Next to exposed cells, untreated control cells 
were harvested by centrifugation and washed two times 
with PBS. Nuclear and cytoplasmic proteins were 
extracted as described below. 
 
RNA isolation, PCR and qRT-PCR assay 
Total RNA was isolated using the RNeasy kit according to 
the instructions of the manufacturer (Qiagen, Venlo, The 
Netherlands). One µg of the obtained RNA was reverse 
transcribed to cDNA using Moloney Murine Leukemia 
Virus (M-MLV; Invitrogen) in a reaction buffer containing 
random hexamer primers (Roche, Basel, Switzerland), 
dNTPs (Roche), and a ribonuclease inhibitor Rnasin 
(Promega, Madison, WI,  USA). A polymerase chain 
reaction (PCR) was performed, using 1µl of the forward 
and reverse primers (table 1) and Reddy Mastermix 
(Thermo Scientific, Waltham, MA, USA).  
 
 
Table 1. Primers and Sequences used for PCR 
Primer sequence 
SF2-ex3 5’-ATGGCACTGGTGTCGTGGAG-3’ 
SF2- x3/4 5’-TCCTTGGGGAGTAACTGCGAC-3’ 
 
 
 
Quantitative real-time was performed using the 
LightCycler 480  SYBR green 1 master Real-Time PCR 
system (Roche). Primers specifically amplifying ASF1 and 
ASF3 isoforms of SRSF1 were used (table 2). Relative 
gene expression was calculated for each sample, as the 
ratio of ASF1 or ASF3 expression to GUS. CCRF-CEM 
wild type cells were used to normalize the expression of 
our target gene in patient samples. 
 
 
 
Table 2. Primers and Sequences used for Real-Time PCR 
Primer sequence 
ASF1_fw 5’ ATCTCATGAGGGAGAAACTGCC 3’ 
ASF1_rev 5’ GTAACTGCGACTCCTGCTGT 3’ 
ASF3_fw 5’ ACACGTATTCTTTTCTTTGACCAGA 3’ 
ASF3_rv 5’ TCTGGCAATTTACTTGGACAACC 3’ 
 
 
Protein Isolation and Western Blot analysis 
Nuclear and cytoplasmic proteins were isolated directly 
after cells were harvested. Pellets were resuspended in 400 
µl of Buffer A (10mM Hepes, pH 7.9, 10mM KCl, 0.1mM 
EDTA, 0.1mM EGTA, 1mM DTT and protease inhibitor) 
and incubated on ice for 15 minutes. Subsequently, 25µl of 
Nonidet P40 (10%) was added to lyse cell membranes. 
After 30 seconds of centrifugation, the supernatant, 
containing  the cytosolic fraction was collected. Next, 100 
µl of Buffer B (20mM Hepe, pH7.9, 0.4 M NaCl, 1mM 
EDTA, 1mM EGTA, 1mM DTT and protease inhibitor) 
was added to the remaining pellet. Tubes were incubated 
in the cold room, while shaking, for 30 minutes. Finally, 
after 2 minutes of centrifugation at 4°C, the supernatant 
was collected which corresponds to nuclear proteins. 
Protein concentrations of the obtained extracts were 
assessed using Biorad DC protein assay (Hercules, CA, 
USA). Western blot was performed as described 
previously by Franke et al.9   
 
Statistical analysis 
Statistical analyses were performed using the IBM SPSS 
Statistics 21 software. Associations between SRSF1 
expression and FPGS splicing alterations as well as 
variables related to drug resistance were analyzed using 
Spearman’s Rho test. Median values were used as cut-off 
values to dichotomize variables, while cut-off values for 
clinical factors were selected based on historical values. 
Kaplan-Meier analysis was used in the univariate analysis 
of event free survival and overall survival in relation to the 
ratio of ASF3 to ASF1. Events included in event free 
survival were relapse and death. All tests were considered 
significant when p-value <0.05. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1; Shifts in splicing of SRSF1 and FPGS genes in ALL 
cell lines upon MTX exposure. A. SRSF1 is expressed in several 
isoforms with the main two being ASF1 and ASF3. The lower band 
represents ASF1 while the upper band corresponds to ASF3. Upon 
exposure to MTX, ASF3 appears in CCRF-CEM/R30dm. B. A 
FPGS splicing analysis by standard PCR spanning exon 5-exon 9 
detected a gradual increase of intron 8 partial retention in CCRF-
CEM/R30dm after exposure to a range of MTX. 
 
RESULTS 
 
Expression of SRSF1 isoforms is associated with 
FPGS splicing alterations in cell lines 
Expression of FPGS splicing alterations and SRSF1 at the 
mRNA and protein level was studied in CCRF-CEM and 
its MTX-resistant subline CCRF-CEM/R30dm, a cell line 
displaying aberrant FPGS splicing and diminished FPGS 
activity. Since elevated levels of intron 8 PR have been 
reported for CCRF-CEM/R30dm, we first investigated 
SRSF1 expression in both these cell lines. CCRF-
CEM/RFC-, a MTX resistant subline displaying decreased 
RFC activity, was included in this study to confirm that 
differences in SRSF1 expression are specific for CCRF-
CEM/R30dm, and not related to general MTX resistance. 
[MTX] in nM 
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Exposure to MTX induced a clear difference in expression 
of isoform ASF3, in CCRF-CEM/R30dm cells in parallel 
to the gradual increase of FPGS intron 8 PR. Both control 
cell lines, CCRF-CEM and CCRF-CEM/RFC-, did not 
show any differences in ASF3 or FPGS intron 8 PR 
expression after exposure to MTX (Figure 1). To confirm 
SRSF1 expression on protein level, proteins isolated from 
the cytoplasmic and nuclear fractions were analyzed. 
While ASF1 expression was clearly present in the nuclei 
of these cell lines, the detection of ASF3 isoform appears 
to be unstable and could not always be observed. Therefore 
the results are inconclusive and need further validation 
(data not shown). 
 
Expression of SRSF1 isoforms and FPGS intron 8 PR 
are correlated in childhood ALL patients 
To explore clinical relevance of our current findings 71 
childhood ALL patient samples were screened for SRSF1 
isoform expression by Real-Time PCR. Subsequently, 
SRSF1 isoforms expression profiles were compared with 
the FPGS splicing profile and clinical data of ALL 
patients. Expression of ASF1, ASF3 and the ratio of ASF3 
to ASF1 were correlated to FPGS splicing profiles using a 
Spearman Rho test. The ratio of ASF3 to ASF1 was found 
to be positively correlated to several splicing alterations 
(Figure 2a). Interestingly, intron 8 PR showed the strongest 
association with the ratio of ASF3 to ASF1 (Figure 2a, 2b), 
followed by retention of intron 5,6 (I5, I6), a simultaneous 
retention of both these introns (I5I6) as well as exon 6, and 
exon 5 skipping (E6, E5). Thereby, 6  out of 11 identified 
alterations seemed to be linked with the relative expression 
of SRSF1 isoforms. Increased levels of ASF3 relative to  
 
ASF1 correlated to a higher ratio of FPGS splicing 
alterations over the wildtype FPGS. Moreover, FPGS 
splicing alterations showed stronger associations with 
ASF3 alone then with ASF1. 
 
The relation of SRSF1 expression with the clinical 
outcome of childhood ALL 
To determine the relation of the ratio ASF3 to ASF1 with 
treatment outcome, a Kaplan-Meier analysis of overall 
survival as well as the event free survival was performed. 
No significant results were found in the complete patient 
cohort for either the total SRSF1 expression, as well as for 
ASF1 and ASF3 variants alone. Previously, in a subgroup 
of patients with low levels of long chain MTX 
polyglutamation, an association between intron 8 PR and 
survival was found. Therefore we studied if SRSF1 
isoform expression is also related to survival in this group 
of patients. Just as for intron 8 PR, in patients displaying 
lower levels of long-chain MTX polyglutamates, increased 
ratio ASF3 to ASF1 were indicative of a worse prognosis 
for event free survival as well as overall survival (Figure 
2c). 
 
DISCUSSION 
 
In the present study we showed that the expression of 
SRSF1 isoforms is associated with alternative FPGS 
splicing in childhood ALL. The levels of ASF3 mRNA 
increased together with FPGS 8 PR after exposure to MTX 
in  MTX-resistant, FPGS-deficient cell line. This 
observation was further supported by an association of 
SRSF1 variant expression to FPGS splicing alteration in 
childhood ALL patient samples on mRNA level. 
  8 PR I5 I6 I5I6 E5 E6 
Ratio  
ASF3/ASF1 
p 
r 
.000 
.407 
.001 
.390 
.001 
.393 
.001 
.393 
.043 
.240 
.009 
.307 
Frequency  71 71 71 71  71 71 
Figure 2; Involvement of SRSF1 in both FPGS splicing and 
MTX resistance in ALL patient samples. A. Non-parametric 
correlations and level of significance derived with a Spearman 
Rho, describe the relation of FPGS splicing alterations. R - 
correlation coefficient, P - p-value (Spearman’s Rho test), N - the 
number of patients evaluated per particular test. B. An 
association between the ratio ASF3 to ASF1 and intron 8 PR has 
been found. C. Associations between the ratio ASF3 to ASF1 and 
MTX resistance in ALL patients displaying low levels of long-
chain MTX polyglutamates. 
 
A 
B 
C Overall Survival 
Low MTX-Glu4-6, low ASF3/ASF1, n=12 
Low MTX-Glu4-6, high ASF3/ASF1, n=11 
Event-Free Survival 
Low MTX-Glu4-6, low ASF3/ASF1, n=11 
Low MTX-Glu4-6, high ASF3/ASF1, n=9 
P = 0.041 
P = 0.048 
Moreover, the ratio of ASF3 to ASF1 is related to both 
overall and event-free survival in ALL patients with low 
level of MTX polyglutamates. Interestingly, intron 8 PR of 
FPGS showed exactly the same association.  
 
To date, it is unclear if the relation between SRSF1 and 
FPGS splicing is causative or if it is merely an association 
due to regulation by a common factor. However, our 
observations point to a relation of SRSF1 expression to 
both alternative splicing of FPGS and MTX resistance and 
therefore suggest differences in regulation by ASF1 or 
ASF3. Because the RS domain is thought to be important 
for protein-protein interactions, ASF3 could attract other 
factors in the process of spliceosome assembly and thereby 
direct the splicing machinery to an alternative splice site.9 
For instance, SRSF1 is predicted by the Human Splicing 
Finder (HSF)10 tool to bind to a spectrum of enhancer 
motifs in intron 8 of FPGS. Both ASF1 and ASF3 contain 
an RNA recognition motif (RRM),8,9 therefore both 
isoforms could select different alternative enhancer motifs 
and thereby affect alternative splicing.  
 
Since we observed differences in expression of  SRSF1 on 
mRNA level between CCRF-CEM and its MTX resistant 
subline, CEM/R30dm, one would expect differences in 
expression of ASF1 and ASF3 on protein level as well. 
This needs to be further evaluated to confirm that ASF3 
has potential to influence the regulation of FPGS splicing. 
Moreover, differences in expression of both isoforms in the 
nuclear fraction should be investigated. Since the RS 
domain is responsible for shuttling between the nucleus an 
the cytoplasm,7,8 the lack of it in ASF3 isoform could have 
significant impact on its subcellular localization and 
consequently function.  
 
Although ASF3 appears in in vitro studies, expression of 
this isoform alone does not seem to be significantly 
associated to FPGS splice variants in patient samples on 
mRNA level. Overall, the ratio of ASF3 to ASF1 is related 
to FPGS splicing aberrations, and therefore both isoforms 
seems to be important in this phenomenon. A role of both 
isoforms in aberrant FPGS splicing is supported by the 
suggestion of dimerization of SRSF1 by Zuo et al.8 The 
function of SRSF1 could be affected by the quantity of 
ASF3/ASF1 heterodimers in comparison to ASF1 
homodimers in MTX sensitive cell lines. Though the main 
functions of SRSF1 involve regulation of splicing, the 
interaction of SRSF1 with a variety of proteins presumably 
enables it to regulate several cellular function, e.g. 
translation and processing of small non coding RNA’s 
(miRNA’s).6 Therefore, SRSF1 could even affect the 
translation of FPGS protein or influence its expression by 
miRNA’s without affecting mRNA levels. For all 
functions, the difference between both isoforms ASF1 and 
ASF3, e.g. the difference between RS domain-dependent 
and RS domain-independent splicing, should be 
elucidated. Differences in function can be studied by 
functional experiments, for instance a model 
overexpressing ASF1 or ASF3 isoforms or siRNA 
mediated knockdown. In the present study CCRF-CEM 
were transduced with lentiviral constructs expressing 
either ASF1 or ASF3 isoform. In this pilot experiment a 
three-fold increase in ASF3 mRNA expression resulted in 
a slight upregulation of intron 8 PR (data not shown).  
 
Taken altogether, our findings suggest that expression of 
ASF1 and ASF3 isoforms is related to FPGS splice 
alterations and MTX resistance. The emerging role of 
alternative splicing and splicing regulators in cancer and 
chemotherapy resistance could generate new therapeutic 
avenues or improvements to the current treatment of 
childhood ALL. Therefore, both FPGS splice variants 
and/or splicing regulators are interesting potential 
prognostic markers for future personalized treatment and 
patient stratification.  
 
ROLE OF THE STUDENT 
From February till June 2014 I worked as intern at the 
department of Pediatric Oncology/Hematology in the 
Cancer Center Amsterdam. After this period I was hired as 
junior researcher to finalize my dataset. I carried out all 
experiments and analyzed the data provided in this paper. 
I also actively participated in the design of particular 
experiments. Weekly meetings with lively discussions 
directed the project towards the success described in this 
paper.  
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